Abstract Library

#4456 Characteristics and clinical outcomes after endoscopic or surgical resection of localised sporadic type III gastric NETs: A national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network

Introduction: Type III gastric neuroendocrine tumours (gNETs) are rare indolent tumours with increasing incidence. Endoscopic resection has recently been described to be a safe strategy to remove small, localised type III gNETs.

Conference:

Presenting Author: Perrier M

Authors: Perrier M, Lefort R, Do Cao C, Hautefeuille V, Wallenhorst T,

Keywords: neuroendocrine neoplasm, stomach, endoscopy, surgery, carcinoid,

#4366 Care of neuroendocrine tumours: The Collaborative of sUrgical Teams for NeuroEndocrine Tumors (CUTNETs)

Introduction: Despite the importance of surgical management, most data on NETs surgical care come from single-centre studies, limiting generalisability. To address these challenges and improve NETs surgical care, a worldwide Collaborative of Surgical Teams for NeuroEndocrine Tumors (CUTNETs) was created.

Conference:

Presenting Author: Hallet J

Authors: Hallet J, Shapiro J, Pascher A, Gaujoux S, Gangi A,

Keywords: surgery, carcinoid, neuroendocrine,

#4293 Efficacy of FOLFOX chemotherapy combined with anti-angiogenic targeted drugs (bevacizumab/surufatinib) in neuroendocrine tumours after progression following multiple lines of therapy: A retrospective study

Introduction: The FOLFOX regimen (combining 5-fluorouracil, leucovorin, and oxaliplatin) has been widely used for treating various cancers, including NETs. However, the effectiveness of combining FOLFOX with antiangiogenic agents in NETs after progression on multiple therapies remains unclear.

Conference:

Presenting Author: Liang Y

Authors: Liang Y, Jia X, Sun Z, Chen J,

Keywords: FOLFOX, chemotherapy, antiangiogenic agents, G3,

#4285 Predictive biomarkers for immunotherapy efficacy in neuroendocrine neoplasms

Introduction: The application of immunotherapy in NENs is still in its early stages. Identifying reliable predictive biomarkers of efficacy is critical for research, enabling better selection of patients who are more likely to respond to immunotherapy and improving treatment success rates.

Conference:

Presenting Author: Liang Y

Authors: Liang Y, Sun Z, Jia X, Chen J,

Keywords: immunotherapy, biomarker, neuroendocrine neoplasm,

#4257 Tolerability and outcomes of neuroendocrine tumors treated with peptide receptor radionuclide therapy and stereotactic body radiation therapy

Introduction: The addition of stereotactic body radiation therapy (SBRT) to patients treated with PRRT may provide synergistic benefit by targeting specific sites of disease that represent areas of tumor heterogeneity. Little is known regarding the efficacy or potential toxicity of this approach. A retrospective review of patients with NEN treated with sequential PRRT and SBRT was performed to provide preliminary outcome and toxicity data to inform further combined treatment strategies.

Conference:

Presenting Author: Myrehaug S

Authors: Nunez Rodriguez J, Ng S, Chen H, Singh S, Hallet J,

Keywords: PRRT, Radiation, SABR, SBRT,